The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TLX | -64.74% | +145.37% | +19.66% | +1,181% |
| S&P | +15.58% | +78.13% | +12.24% | +172% |
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TX250, TX591, and TX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
No news articles found for Telix Pharmaceuticals.
| Q2 2024 | YOY Change | |
|---|---|---|
| Revenue | $188.96M | 0.0% |
| Gross Profit | $123.88M | 0.0% |
| Gross Margin | 65.56% | 0.0% |
| Market Cap | $6.23B | 0.0% |
| Net Income | $11.68M | 0.0% |
| EBITDA | $15.75M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2024 | YOY Change | |
|---|---|---|
| Net Cash | $118.84M | 0.0% |
| Accounts Receivable | $89.33M | 0.0% |
| Inventory | 30.8 | 0.0% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $18.36M | 0.0% |
| Short Term Debt | $3.78M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -437.59% | 0.0% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | $27.12M | 0.0% |
| Operating Free Cash Flow | $33.61M | 0.0% |
| Metric | Q1 2024 | Q2 2024 | YoY Change |
|---|---|---|---|
| Price to Book | 53.99 | 34.40 | - |
| Price to Tangible Book Value | 238.34 | 90.88 | - |
| Enterprise Value to EBITDA | 128.97 | 409.27 | - |
| Total Debt | $19.08M | $22.14M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
